Document Detail


Oxidative-antioxidative systems and their relation with serum S100 B levels in patients with schizophrenia: effects of short term antipsychotic treatment.
MedLine Citation:
PMID:  17459548     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Oxidative stress may be a contributing factor in the etiopathophysiology of schizophrenia, which may be exacerbated by the treatment with antipsychotics with pro-oxidant properties. Increased levels of S100 B are associated with neurodegenerative disorders, including schizophrenia. The aim of the present study was to investigate the role of oxidative cell damage in the pathogenesis of schizophrenia. Forty patients who fully met the fourth Diagnostic and Statistical Manual of Mental Disorders criteria for schizophrenia and 35 healthy control subjects were included in the study. Serum S100 B level was determined to investigate brain damage. Plasma malondialdehyde (MDA) levels and susceptibility of red blood cell (RBC) to oxidation were determined to investigate the oxidative status and plasma vitamin E, vitamin C, serum total carotenoid levels and total antioxidant capacity and RBC superoxide dismutase (SOD) and whole blood glutathione peroxidase activities were measured to investigate the antioxidative defence before and after 6 weeks of antipsychotic treatment. Plasma MDA and serum S100 B levels and RBC-SOD activity were significantly higher in the schizophrenia group than those of the control group. Treatment did not modify any of the oxidative-antioxidative system parameters or serum S100 B levels. S100 B level was significantly higher in patients with negative symptoms than the patients with positive symptoms and the control subjects. S100 B levels were significantly reduced after 6 weeks of treatment in patients with negative symptoms. The results of the present study might support the oxidative cell injury hypothesis of the schizophrenia. Furthermore, the underlying mechanisms of the subgroups of schizophrenia might be different as suggested by the increased S100 B levels and its decrement after treatment in patients with negative symptoms.
Authors:
Asli Sarandol; Selcuk Kirli; Cengiz Akkaya; Aysun Altin; Meral Demirci; Emre Sarandol
Related Documents :
3286598 - Endotoxemia produces an increase in arterial but not venous lipid peroxides in sheep.
9690328 - Reduced status of plasma total antioxidant capacity in schizophrenia.
3377528 - Experimental burn-induced changes in lipid peroxide levels, and activity of superoxide ...
19192028 - Acute effect of nut consumption on plasma total polyphenols, antioxidant capacity and l...
23549818 - Reversible infertility associated with testosterone therapy for symptomatic hypogonadis...
10680658 - Correlation of periovulatory serum and fecal progestins in the domestic dog.
Publication Detail:
Type:  Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't     Date:  2007-03-21
Journal Detail:
Title:  Progress in neuro-psychopharmacology & biological psychiatry     Volume:  31     ISSN:  0278-5846     ISO Abbreviation:  Prog. Neuropsychopharmacol. Biol. Psychiatry     Publication Date:  2007 Aug 
Date Detail:
Created Date:  2007-07-27     Completed Date:  2007-10-31     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8211617     Medline TA:  Prog Neuropsychopharmacol Biol Psychiatry     Country:  England    
Other Details:
Languages:  eng     Pagination:  1164-9     Citation Subset:  IM    
Affiliation:
Uludag University Medical Faculty, Department of Psychiatry, 16059 Bursa, Turkey. asli@uludag.edu.tr
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Antipsychotic Agents / blood*,  pharmacology
Ascorbic Acid / blood
Carotenoids / blood
Case-Control Studies
Female
Humans
Male
Malondialdehyde / blood
Middle Aged
Nerve Growth Factors / blood*
Oxidative Stress / drug effects,  physiology*
S100 Proteins / blood*
Schizophrenia / blood*,  drug therapy
Superoxide Dismutase / blood
Vitamin E / blood
Chemical
Reg. No./Substance:
0/Antipsychotic Agents; 0/Nerve Growth Factors; 0/S-100 calcium-binding protein beta subunit; 0/S100 Proteins; 1406-18-4/Vitamin E; 36-88-4/Carotenoids; 50-81-7/Ascorbic Acid; 542-78-9/Malondialdehyde; EC 1.15.1.1/Superoxide Dismutase

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Characteristics and clinical correlates of restless legs syndrome in schizophrenia.
Next Document:  Treatment with risperidone for 4 weeks increased plasma 3-methoxy-4-hydroxypnenylglycol (MHPG) level...